Show simple item record

dc.contributor.authorVon Rohr, A
dc.contributor.authorAnderson, Heather
dc.contributor.authorMcIntosh, R
dc.contributor.authorThatcher, Nick
dc.date.accessioned2010-07-17T10:19:11Z
dc.date.available2010-07-17T10:19:11Z
dc.date.issued1991
dc.identifier.citationPhase II study with mitomycin, ifosfamide and carboplatin in inoperable non-small cell lung cancer. 1991, 27 (9):1106-8 Eur. J. Canceren
dc.identifier.issn0959-8049
dc.identifier.pmid1659850
dc.identifier.doi10.1016/0277-5379(91)90303-U
dc.identifier.urihttp://hdl.handle.net/10541/107854
dc.description.abstractIn a phase II study of non-small cell lung cancer a new chemotherapy combination of mitomycin 6 mg/m2 intravenously on day 1, carboplatin 400 mg/m2 intravenously on day 1 and ifosfamide with mesna 5 g/m2 intravenously over 24 hours on day 1 was evaluated. A maximum of four chemotherapy cycles was given at intervals of 4 weeks to 34 patients with progressive, inoperable disease. 1 complete and 10 partial remissions were documented, the overall response rate being 32.4%. In a further 13 patients (38.2%) the previously progressing tumours remained stable for at least 6 weeks. The median time to progression for responding patients was 184 days. The median survival time for the whole group has not yet been reached at 293 days. A considerable but easily manageable myelosuppression was the principal toxicity despite a "no dose reduction" policy. Indeed, the dose intensity of the chemotherapy actually given was extremely close (97%) to that intended on protocol. In conclusion, the regimen is active in patients with advanced non-small cell lung cancer but requires regular haematological monitoring to prevent morbidity resulting from myelotoxicity.
dc.language.isoenen
dc.subjectHaematologic Diseasesen
dc.subjectLung Canceren
dc.subject.meshAged
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCarboplatin
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.meshDrug Evaluation
dc.subject.meshFemale
dc.subject.meshHematologic Diseases
dc.subject.meshHumans
dc.subject.meshIfosfamide
dc.subject.meshLung Neoplasms
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshMitomycins
dc.subject.meshPrognosis
dc.subject.meshTime Factors
dc.titlePhase II study with mitomycin, ifosfamide and carboplatin in inoperable non-small cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital & Holt Radium Institute, Manchester, U.K.en
dc.identifier.journalEuropean Journal of Canceren
html.description.abstractIn a phase II study of non-small cell lung cancer a new chemotherapy combination of mitomycin 6 mg/m2 intravenously on day 1, carboplatin 400 mg/m2 intravenously on day 1 and ifosfamide with mesna 5 g/m2 intravenously over 24 hours on day 1 was evaluated. A maximum of four chemotherapy cycles was given at intervals of 4 weeks to 34 patients with progressive, inoperable disease. 1 complete and 10 partial remissions were documented, the overall response rate being 32.4%. In a further 13 patients (38.2%) the previously progressing tumours remained stable for at least 6 weeks. The median time to progression for responding patients was 184 days. The median survival time for the whole group has not yet been reached at 293 days. A considerable but easily manageable myelosuppression was the principal toxicity despite a "no dose reduction" policy. Indeed, the dose intensity of the chemotherapy actually given was extremely close (97%) to that intended on protocol. In conclusion, the regimen is active in patients with advanced non-small cell lung cancer but requires regular haematological monitoring to prevent morbidity resulting from myelotoxicity.


Files in this item

This item appears in the following Collection(s)

Show simple item record